Biotech Startups
9,915 companies tagged Biotech, with their investors and founders.
Aradigm develops financial and delivery infrastructure for cell and gene therapies, partnering with payers, providers, manufacturers, and patients to enable sustainable access to transformative treatments through a pass-through business model.
2 investors
Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy. The platform generates stable, homogenous ADCs for oncology applications without requiring antibody re-engineering.
2 investors
Arase Therapeutics develops first-in-class oncology therapeutics that target ADP-ribose Hydrolases, novel proteins in cancer stress pathways. The company focuses on developing new cancer treatments for patients with various cancer types.
2 investors
Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies. Founded on technology from Alfred Health and Monash University, it operates internationally with offices in Melbourne, Australia and Oxford, UK.
2 investors
2 investors
Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets. It develops oral therapies with an emphasis on immunology and oncology.
2 investors
Archon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.
2 investors
Arcomedlab develops personalized medicine implants and drug-releasing systems to improve patient quality of life. The company designs and manufactures medical devices including orthopedic and dental implants using advanced technologies such as 3D printing.
2 investors
Arc Therapeutics is a stealth-stage biopharmaceutical company developing medicines for central nervous system (CNS) conditions with high unmet medical needs.
2 investors
Arctoris operates as a partnership research organisation providing automated wet lab biology R&D and data generation services, using its Ulysses platform combining robotics, data science, and biological expertise to produce reproducible, AI-ready experimental data. It serves biotech, techbio, and pharma companies to support drug discovery.
2 investors
Arctx Medical develops an investigational cooling therapy device designed to treat acute pancreatitis by reducing pancreatic inflammation through localized temperature control. The company targets patients with acute inflammatory pancreatic disease to prevent progression to systemic illness and organ failure.
2 investors
2 investors
Arevo develops a proprietary crop nutrition technology (Arginex) that activates the plant root zone to improve nutrient uptake, offering growers an alternative to conventional mineral fertilisers. Based on research from the Swedish University of Agricultural Sciences, it serves agricultural producers and formulators seeking to reduce reliance on chemical inputs.
2 investors
Argon AI provides an AI-native workspace designed for life sciences, clinical, and commercial teams that automates research workflows, generates insights from medical data, and accelerates drug development processes.
2 investors
Arima Genomics develops DNA-based cancer diagnostics that combine genomic sequence with 3D genome structural information (via Hi-C sequencing) to detect fusions, rearrangements, ecDNA, and other structural drivers of cancer. It serves clinicians and biopharma partners through its Aventa clinical testing brand and translational science collaborations, using routine FFPE tumor samples to guide diagnosis and therapy selection.
2 investors
ARIZ Precision Medicine develops cancer treatments that combine biological and nanotechnology approaches to target the genetic and epigenetic drivers of cancer, aiming to kill cancer cells while leaving healthy cells undamaged. The company designs targeted drug delivery systems intended to concentrate drugs inside cancer cells.
2 investors
ArkVax develops glycoconjugate vaccines for animal health using genetic engineering of bacterial cells, aiming to provide broader protection than current vaccines. Its technology targets antibacterial and zoonotic diseases to help combat antimicrobial resistance in both livestock and humans.
2 investors
Armatus Bio develops vectorized RNA interference therapeutics targeting genetic neurological and neuromuscular diseases.
2 investors
2 investors
Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics. The platform serves pharmaceutical researchers and biotechnology companies developing treatments for genetic disorders and other disease areas.
2 investors
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
2 investors
Aroa Biosurgery develops soft tissue repair and wound management products based on its AROA ECM extracellular matrix platform, including bioscaffolds for acute and chronic wounds, surgical reconstruction, and hernia repair. Its products, such as Endoform, Myriad Matrix, and Symphony, are used by surgeons and clinicians for soft tissue repair and reconstruction.
2 investors
Arontier is a company that applies artificial intelligence to drug discovery, using proprietary technology and data to develop treatments for incurable and rare diseases. Founded in 2017, it collaborates with companies, experts, and scholars on new medicines and genetic editing.
2 investors
Arpelos Biosciences is a seed-stage biotech company developing multivalent targeted therapeutics aimed at high potency and selectivity, drawing on compute, immunology, and protein engineering. It is based in Kendall Square (Cambridge, Massachusetts).
2 investors